| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_23f5e367b9090dcf9312517fd445dad1 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6831
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-289
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-17
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2893
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6849
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6803
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2812
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2815
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2878 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K51-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-68
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate |
2020-01-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3de3d9bcb6a2958ae53b29f3ae712034
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_abc7a67cd60cff7b0d13d2e8616d1f02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_96f00fac8575e2f9ac70211be84a9f86 |
| publicationDate |
2021-10-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CN-113490504-A |
| titleOfInvention |
Use of Anti-CD45 Antibody Drug Conjugates (ADCs) in Cell Therapy |
| abstract |
The present invention provides a method for depleting CD45+ cells to promote the acceptance of CAR-expressing immune cells in a human patient undergoing chimeric antigen receptor (CAR) immunotherapy. The anti-CD45 antibody drug conjugate (ADC) is administered as a conditioning regimen to human patients receiving autologous or allogeneic CAR-expressing immune cells such that CAR-expressing immune cells are accepted by the human patient. The compositions and methods of the present invention can be used in combination with CAR therapy to treat a variety of pathologies, including autoimmune diseases and cancer. |
| priorityDate |
2019-01-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |